Adjuvant Nivolumab Plus Chemoradiotherapy Meets DFS End Point in Locally Advanced HNSCC
Adjuvant nivolumab plus chemoradiotherapy improved disease-free survival in resected, locally advanced head and neck squamous cell carcinoma.
Related Articles
Three lessons from “The Fox and the Grapes” to inform precision oncology in the older adult
Practical Applications:
Emerging strategies to investigate the biology of early cancer
Nature Reviews Cancer – Understanding the early steps of cancer development is crucial for cancer prevention. In this Review, the authors summarize the advantages and…
SEN Radio parts ways with cricket journalist over Palestine social media posts
SEN Radio has parted ways with prominent cricket journalist Peter Lalor halfway through Australia’s tour of Sri Lanka over his social media activity relating to…
Call for EIC – CA: A Cancer Journal for Clinicians – Wiley Online Library
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
A novel therapy with a rational design for AML
In this issue of Blood, Liu et al1 report the results of a phase 1 clinical trial using pegcrisantaspase (PegC) in combination with venetoclax in relapsed
Surgical & Pathology Interventions Improve Lung Cancer… : Oncology Times
An abstract is unavailable.
A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT
Key PointsRuxolitinib therapy was associated with improvements in lung function for participants with BOS.Clinical responses were more commonly observed in
Balstilimab Combo Improves ORR in MSS mCRC Without Liver Metastases
Balstilimab plus botensilimab improved ORR over botensilimab alone in MSS mCRC without liver metastases, per phase 2 data.
Kathryn Schmitz, José Zevallos named interim director, interim deputy director at UPMC Hillman – The Cancer Letter
UPMC Hillman Cancer Center and the University of Pittsburgh announced that Kathryn Schmitz was appointed interim director of UPMC Hillman. José P. Zevallos was appointed as…
